A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy

European Urology

Volumn 64, Issue 6, 2013, Pages 895-902

  Zumsteg, Zachary S ^a   Spratt, Daniel E ^a   Pei, Isaac ^a   Zhang, Zhigang ^a   Yamada, Yoshiya ^a   Kollmeier, Marisa ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen deprivation; Dose escalation; Intermediate risk; Prostate cancer; Risk stratification

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL DECISION MAKING; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; STRATIFICATION; TUMOR BIOPSY;

ANDROGEN DEPRIVATION; DOSE ESCALATION; INTERMEDIATE RISK; PROSTATE CANCER; RISK STRATIFICATION;

AGED; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84887405314     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.033     Document Type: Article

References (32)

1. P.A. Ganz, J.M. Barry, and W. Burke National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer Ann Intern Med 156 2012 591 595
2. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2010 203 213
3. P. Stattin, E. Holmberg, J.E. Johansson, L. Holmberg, J. Adolfsson, and J. Hugosson Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study J Natl Cancer Inst 102 2012 950 958
4. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
5. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
6. A.C. Raldow, C.J. Presley, and J.B. Yu The relationship between clinical benefit and receipt of curative therapy for prostate cancer Arch Intern Med 172 2012 362 363
7. S. Swisher-McClure, C.E. Pollack, and J.P. Christodouleas Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer Int J Radiat Oncol Biol Phys 83 2012 8 15
8. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
9. A.C. Reese, P.M. Pierorazio, M. Han, and A.W. Partin Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system Urology 80 2012 1075 1079
10. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459 3464
11. Z.S. Zumsteg, D.E. Spratt, and X. Pei Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy Int J Radiat Oncol Biol Phys 85 2013 1012 1017
12. A.V. D'Amico, A.A. Renshaw, and K. Cote Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease J Clin Oncol 22 2004 3726 3732
13. P.L. Nguyen, M.H. Chen, W.J. Catalona, J.W. Moul, L. Sun, and A.V. D'Amico Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors Int J Radiat Oncol Biol Phys 73 2009 659 664
14. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
15. Z.S. Zumsteg, and M.J. Zelefsky Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13 2012 e259 e269
16. Z.A. Alicikus, Y. Yamada, and Z. Zhang Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer Cancer 117 2011 1429 1437
17. J. Fine, and R. Gray A proportional hazards model for the sub distribution of a competing risk J Am Stat Assoc 94 1999 496 509
18. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
19. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
20. R.K. Valicenti, K. Bae, and J. Michalski Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06 Int J Radiat Oncol Biol Phys 79 2011 1323 1329
21. D. Krauss, L. Kestin, and H. Ye Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1064 1071
22. K.O. Castle, K.E. Hoffman, and L.B. Levy Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 85 2013 693 699
23. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
24. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
25. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
26. P.C. Albertsen, J.A. Hanley, and G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248 1253
27. A. Gallina, F.K. Chun, and N. Suardi Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer BJU Int 101 2008 1513 1518
28. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and L.L. Egevad The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
29. F. Dong, C. Wang, and A.B. Farris Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system Am J Surg Pathol 36 2010 838 843
30. M.J. Zelefsky, X. Pei, and J.F. Chou Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes Eur Urol 60 2011 1133 1139
31. M.W. Kattan, M.J. Zelefsky, and P.A. Kupelian Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer J Clin Oncol 21 2003 4568 4571
32. D.G. Ingram, and M.W. Kattan Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test J Urol 184 2010 1937 1941